Theratechnologies Reports on its Annual Meeting of Shareholders
Theratechnologies (NASDAQ: THTX) held its annual virtual shareholders meeting on May 29, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Theratechnologies (NASDAQ: THTX) held its annual virtual shareholders meeting on May 29, 2025. During the meeting, shareholders elected eight directors to the Company's Board for a one-year term. All proposed candidates were successfully elected with approval rates ranging from 77.98% to 84.03%. Joseph Arena received the highest shareholder support with 84.03% votes in favor, while Dawn Svoronos received 77.98% of favorable votes.
Additionally, shareholders appointed KPMG LLP as the Company's auditors for the current fiscal year and approved an omnibus long-term incentive plan benefiting directors, executive officers, and employees of the Company and its subsidiaries.
Details
News Market Reaction – THTX
The recorded move for THTX in the trading session of this news was +0.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting.
Shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term, appointed KPMG LLP as the Company’s auditors for the current fiscal year and approved the adoption of an omnibus long-term incentive plan for the benefits of the directors, executive officers and employees of the Company and those of its subsidiaries.
All candidates proposed for the position of director were elected in the following proportion:
| FOR | % FOR | ABSTENTION | % ABSTENTION | |
| Joseph Arena | 20,473,944 | 3,890,222 | ||
| Frank Holler | 19,089,786 | 5,274,380 | ||
| Paul Lévesque | 19,027,772 | 5,336,394 | ||
| Andrew Molson | 19,066,145 | 5,298,021 | ||
| Dawn Svoronos | 18,998,230 | 5,365,936 | ||
| Elina Tea | 19,163,502 | 5,200,664 | ||
| Dale Weil | 19,005,768 | 5,358,398 | ||
| Jordan Zwick | 19,618,725 | 4,745,441 | ||
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X (formerly Twitter).
Contacts:
Investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
pdubuc@theratech.com
438-315-6608
Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
communications@theratech.com
514-336-7800
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.